Attention deficit/hyperactivity disorder children with a 7-repeat allele of the dopamine recepter D4 gene have extreme behavior but normal performance on critical neuropsychological tests of attention by Swanson, J. et al.
Attention deficityhyperactivity disorder children with
a 7-repeat allele of the dopamine receptor D4 gene
have extreme behavior but normal performance on
critical neuropsychological tests of attention
James Swanson*†‡, Jaap Oosterlaan§, Michael Murias*, Sabrina Schuck*, Pamela Flodman*, M. Anne Spence*,
Michael Wasdell*, Yuanchun Ding¶i, Han-Chang Chi¶, Moyra Smith*, Miranda Mann**, Caryn Carlson**,
James L. Kennedy††, Joseph A. Sergeant§, Patrick Leung‡‡, Ya-Ping Zhangi, Avi Sadeh§§, Chuansheng Chen¶¶,
Carol K. Whalen¶¶, Kimberley A. Babb¶¶, Robert Moyzis¶, and Michael I. Posner†
*Department of Pediatrics, University of California, Irvine, CA 92612; ¶Departments of Biological Chemistry and ¶¶Psychology and Social Behavior, University
of California, Irvine, CA 92697; §Department of Clinical Neuropsychology, Free University, Amsterdam, De Boelelaan 1109 1081 HV Amsterdam, The
Netherlands; †The Sackler Institute for Developmental Psychobiology, Department of Psychiatry, Joan and Sanford I. Weill Medical College of Cornell
University, 1300 York Avenue, Box 140, New York, NY 10021; ††Neurogenetics Section, Centre for Addiction and Mental Health, University of Toronto,
Toronto, ON, Canada M5T 1R8; **Department of Psychology, University of Texas, Mezes 330, Austin, TX 78712; ‡‡Department of Psychology, Chinese
University of Hong Kong, 3yF, Sino Building, Shatin, New Territories of Hong Kong; iLaboratory of Cellular and Molecular Evolution, Kunming Institute of
Zoology, Chinese Academy of Sciences, Kunming 650223, People’s Republic of China; and §§Department of Psychology, University of Tel Aviv, Ramat Aviv,
Tel Aviv 69978, Israel
Contributed by Michael I. Posner, February 17, 2000
An association of the dopamine receptor D4 (DRD4) gene located
on chromosome 11p15.5 and attention deficityhyperactivity disor-
der (ADHD) has been demonstrated and replicated by multiple
investigators. A specific allele [the 7-repeat of a 48-bp variable
number of tandem repeats (VNTR) in exon 3] has been proposed as
an etiological factor in attentional deficits manifested in some
children diagnosed with this disorder. In the current study, we
evaluated ADHD subgroups defined by the presence or absence of
the 7-repeat allele of the DRD4 gene, using neuropsychological
tests with reaction time measures designed to probe attentional
networks with neuroanatomical foci in D4-rich brain regions.
Despite the same severity of symptoms on parent and teacher
ratings for the ADHD subgroups, the average reaction times of the
7-present subgroup showed normal speed and variability of re-
sponse whereas the average reaction times of the 7-absent sub-
group showed the expected abnormalities (slow and variable
responses). This was opposite the primary prediction of the study.
The 7-present subgroup seemed to be free of some of the neuro-
psychological abnormalities thought to characterize ADHD.
Dopamine plays an important role in normal attention (1) anddisorders of attention (2, 3). Recently, this role of dopamine
has stimulated molecular genetic studies (4) of attention deficity
hyperactivity disorder (ADHD), the most prevalent psychiatric
disorder of childhood recognized in the United States. The
dopamine receptor genes (5) have been investigated in other
psychiatric disorders (e.g., schizophrenia; see refs. 6 and 7), and
the background from this work set the stage for our molecular
genetic investigations of ADHD.
In our program of research, we adopted a candidate gene
approach, focusing on the dopamine receptor D4 (DRD4) gene
on chromosome 11p15.5. This gene has a polymorphism in a
coding region—a variable number of tandem repeats of a
48-base pair sequence in exon 3 (8) that codes for variation in the
third intracellular loop of the D4 receptor, which may have
functional significance. In vitro studies suggest that the receptor
encoded by the DRD4 7-repeat allele may be subsensitive to
endogenous dopamine compared with the receptor encoded by
the 2-repeat allele (9), although this apparently is not due merely
to the length of the third intracellular loop (10). Initially, in our
clinical studies we used population-based (11) and family-based
(12) association designs, which suggested that the DRD4 7-re-
peat allele is associated with ADHD, but with a small relative
risk (about 1.5). A review of the recent literature (4) revealed
that two independent groups have confirmed this association in
children (13, 14), but one group did not (15). The pattern of
replication has held up in several other case studies not yet
published.
The presence of the DRD4, 7-repeat allele is not a necessary
condition (about half of the ADHD cases did not have a 7-repeat
allele) (11, 12) or a sufficient condition (about 20% of ethnically
matched control subjects did have a 7-repeat allele) (11). This is
not surprising because it is generally assumed that ADHD has
many causes and that any clinical sample is likely to be hetero-
geneous rather than homogeneous with respect to etiology (see
ref. 16). Still, an etiological role of the DRD4 7-repeat allele is
tantalizing, for several reasons, including a long history of
dopamine theories of ADHD (see ref. 17); the location of the
variable length 48-bp repeat in a coding region of the gene
(5–10); and the neuroanatomical foci of the gene product, D4
receptors, in cortical areas including the anterior cingulate gyrus
(6), a brain region that plays an important role in normal
attention (refs. 18–21; also see ref. 1) and abnormal attention
(ref. 22; also see refs. 3 and 16).
In the framework of a multidisciplinary research program, the
present study was designed by a cross-national group (XNAT),
from the Netherlands, China, Israel, Canada, and multiple sites
in the United States. There were two specific aims of this XNAT
project: to select a theoretically based set of neuropsychological
tests to distinguish ADHD and control subjects on quantitative
measures of attention and to use the selected test battery to
contrast patterns of abnormalities in subgroups of ADHD
children defined by the presence and absence of the DRD4
7-repeat allele.
Background
The diagnosis of ADHD is based on subjective reports by parents
and teachers of symptoms of inattention, hyperactivity, and
Abbreviations: ADHD, attention deficityhyperactivity disorder; DRD4, dopamine receptor
D4; ODD, oppositional defiant disorder; RT, reaction time; TDT, transmission disequilibrium
test.
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impulsivity (23). In the U.S., this diagnosis usually results in
pharmacological treatment with stimulant medication, such as
methylphenidate or amphetamine. Currently, ADHD is diag-
nosed and treated with stimulant medications in about 2 million
children per year in the U.S. and less frequently but increasingly
around the world (ref. 24; also see ref. 16 for a review).
A major site of action of stimulant drugs is the dopamine
synapse (see refs. 5 and 6). Amphetamine and methylphenidate
stimulate the release andyor block the re-uptake of dopamine
(see refs. 25 and 26), which increase the levels of extracellular
dopamine in the synaptic space, although presynaptic regulation
may change this over time (27). At clinical doses, this results in
decreased activity, inattention, and impulsivity (i.e., decreased
symptoms of ADHD). These pharmacological properties of the
stimulants were influential in the development of site-of-action
theories of ADHD, which focus on possible abnormalities in
dopamine pathways of the brain and suggest that the stimulants
may correct or compensate for the core deficits of the disorder
(see ref. 17; also see refs. 3 and 16). In previous reviews of the
neuroanatomical and molecular genetic bases of ADHD (2, 4,
16, 28), we proposed a variant of the dopamine theory of ADHD
based on reduced activity in the mesolimbic dopamine pathway
due to multiple factors, including the possibility that the DRD4
7-repeat allele might code for subsensitive DA receptors in the
frontal lobes and produce underactivity in the neural networks
involved in executive functions (3, 20, 29).
Because there are so many (.50,000) genes expressed in brain,
it is typically assumed that an initial report of an association with
any one gene will be a false positive (30). However, when
multiple replications of the same association are reported with
family-based association methods, the assumption of a false
positive association is discounted. In the literature, multiple
replications of a candidate gene association for a psychiatric
disorder is unusual (see ref. 30), but this has occurred for the
DRD4 gene in studies of ADHD (see ref. 4).
This success may be due to the use of relevant theories [i.e.,
the neuroanatomical network theory (1, 31) and the DA theory
of ADHD (17)], which led us to select DRD4 as a candidate
gene. These theories also suggest investigations of performance
on specific neuropsychological tests that depend on function of
D4-rich brain regions. In the present study of children with
ADHD, we hypothesized that, in comparison to a control group,
the 7-present subgroup would show larger abnormalities than the
7-absent subgroup in performance of the selected neuropsycho-
logical tests of attention. The XNAT group developed a protocol
that was approved by the Institutional Review Board of the
University of California at Irvine for a study of neuropsycho-
logical and molecular genetic bases of ADHD.
Methods
Our ADHD subjects were drawn from a cohort of ADHD
subjects (n 5 96) and control subjects (n 5 48) at the University
of California at Irvine, one of the six sites of the Multimodality
Treatment Study of Children with ADHD (MTA); (32). The
ADHD children were diagnosed by psychiatric interviews and
questionnaires about psychopathological behavior that are com-
ponents of a research assessment battery for ADHD (see ref. 33).
The inclusion criteria for our clinical subjects included a
DSM-IV diagnosis of ADHD-Combined Type, including the
endorsement of at least six of nine symptoms of inattention and
six of nine symptoms of hyperactivityyimpulsivity. The control
subjects were unscreened volunteers from classrooms in the
same schools and grades of the ADHD subjects in the MTA
study. The volunteer rate in each classroom was over 50% of the
enrolled students, with one control child selected from randomly
selected classrooms. A restriction on gender was imposed to
provide matching to the ADHD group for the percentage of
males and females.
To participate in the present study, in addition to the MTA
consent process, written consent of parents and assent of chil-
dren was obtained from 44 ADHD children and 21 control
children to undergo 2 days of neuropsychological assessment in
the XNAT protocol. As part of the MTA assessment, extreme
parent and teacher ratings (0, ‘‘not at all’’; 1, ‘‘just a little’’; 2,
‘‘pretty much’’; and 3, ‘‘very much’’) of ADHD items on the
Swanson, Nolan, and Pelham (SNAP) rating scale (33) were
required. The average rating per item can be used to document
severity of symptoms in both domains for ADHD (inattention
and hyperactivityyimpulsivity), and a SNAP score above 2.0 is
considered severe. Ratings were also obtained for another
disruptive behavior disorder of childhood, oppositional defiant
disorder (ODD), that is often comorbid with ADHD. As ex-
pected, the overall ADHD group had higher average symptom
ratings than the control group for parent ratings of inattention
(2.27 vs. 0.43) and hyperactivityyimpulsivity (2.07 vs. 0.21), as
well as for ODD (1.61 vs. 0.35). The teacher ratings also verified
symptom severity of inattention (2.32 vs. 0.65), hyperactivityy
impulsivity (2.0 vs. 0.35), and ODD (1.45 vs. 0.21). Only children
in the ADHD group (57%) were being treated with stimulant
medication during the time when they participated in this study,
but children being treated with stimulants did not take medica-
tion for at least 24 h before the administration of the neuropsy-
chological tests. Because of the recruitment strategy of the MTA
study, the ADHD group was slightly but significantly older than
the control group (141 vs. 134 months). No significant differ-
ences were found (see Table 1) when the ADHD and control
groups were compared on gender (80% of the ADHD and 81%
of the control group were boys) and ethnicity (e.g., 68% of the
ADHD group and 71% of the control group were Caucasian).
To address our first aim, we selected three neuropsychological
tasks for the XNAT battery. Directed by the neuroanatomical
network theory of attention proposed by Posner and Raichle (1,
31), we chose tasks to probe the functions of three brain regions
implicated in the attentional deficits in ADHD (anterior cingu-
late, right dorsolateral prefrontal, and posterior parietal). We
Table 1. Demographics, ADHD symptoms, and psychometric test
scores of the groups
ADHD,
n 5 44
Control,
n 5 21
Demographics
Age, months 141.2 134.3
% Medicated 54.5 0.0
% Male 79.5 81.0
% Caucasian 68.2 71.4
% Non-Black Hispanic: Mexican 06.8 14.3
% African-American 02.3 00.0
% Asian: Japanese 00.0 04.8
% Other 22.7 09.5
Parent-SNAP
Inattention 2.3 0.4
Hyperactivity/impulsivity 2.1 0.2
ODD 1.6 0.3
Teacher-SNAP
Inattention 2.3 0.7
Hyperactivity/impulsivity 2.2 0.2
ODD 1.5 0.4
Psychometric tasks
WIAT reading 98.7 113.9
WIAT math 98.7 112.0
WIAT spelling 97.4 110.0
WISC block design 10.9 11.9
WISC vocabulary 10.3 11.9
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also used controlled experimental procedures to maximize the
degree to which the ADHD subjects were cooperating and
following the instructions of these tasks, which has been crucial
in neuropsychological evaluation of other patient groups (see
ref. 34). This was accomplished by making frequent checks of
subjects while they were performing the tasks (with redirection
provided by the experimenter, if necessary) and by giving
frequent rest periods.
We administered the following tasks: (i) a color-word task (35)
to probe the executive function network linked to anterior
cingulate brain regions and to conflict resolution (20); (ii) a
cued-detection task (36) to probe the orienting and alerting
networks linked to posterior parietal and frontal brain regions
and to shifting and maintenance of attention (37); and (iii) a
go-change task (38, 39) to probe the alerting network (and the
ability to initiate a series of rapid response in a choice reaction
time task), as well as the executive network (and the ability to
inhibit a response and re-engage to make another response) (40).
Within-task conditions were designed to probe hypotheses about
specific attentional deficits of ADHD children, but an overall
measure of performance was developed (see below) and used in
this paper.
To address the second aim of the XNAT project, we geno-
typed as many of our ADHD subjects as possible. Of these 44
ADHD families recruited and consented for the neuropsycho-
logical assessment, 32 also provided written consent and assent
for the collection of blood samples for genetic analysis. DNA was
extracted, and PCR assays previously reported (see refs. 7, 8, 11,
and 12) were used to amplify the 48-bp VNTR of the DRD4
gene. Of the 32 ADHD subjects, 40.6% (13y32) had at least one
7-repeat allele and were assigned to the 7-present subgroup, and
59.4% (19y32) did not have a 7-repeat allele and were assigned
to the 7-absent subgroup. The percentage of ADHD subjects
with the 7-present genotype was slightly lower than the percent-
age (about 50%) reported in our previous studies (11, 12).
Results
To address our first specific aim, we compared the performance
of the total ADHD group (n 5 44) and the control group (n 5
21) on the color-word, cued-detection, and go-change tasks. We
used an overall summary score to reflect the average speed
across all of the specific conditions of each task, and for each task
we calculated the average reaction time (RT) and standard
deviation (SD) of RT for each subject. A simple t test (equal
variances not assumed) was used to contrast the groups on each
of two summary scores (RT and SD) for each task.
The sensitive measures of speed (RT) and variability (SD) of
performance revealed large group differences (see Fig. 1).
Across all conditions of each task, the ADHD group was slower
(longer mean RTs) and more variable (greater within-subject SD
of RTs) than the control group. For each ADHD versus control
group comparison on RT and SD summary scores, the t tests
were significant. In addition to performing a significance test, the
magnitude of the ADHD-control group differences were esti-
mated by calculating effect sizes (the standardized mean differ-
ence between groups) for the RT and SD summary scores, which
varied from moderate to large across the three tasks in the
XNAT battery: color-word, RT 5 0.49 (P 5 0.054) and SD 5
0.72 (P 5 0.005); cued-detection, RT 5 0.68 (P 5 0.009) and
SD 5 0.89 (P 5 0.001); go-change, RT 5 0.86 (P 5 0.002) and
SD 5 0.80 (P 5 0.003).
These findings confirm the sensitivities of the quantitative
traits measured by the XNAT battery, at least for contrasts of a
refined phenotype of ADHD used for the MTA study (severe
cases with the combined type) and a control group. These data
do not support the view that these ADHD children have a hasty
style of responding that results in fast and inaccurate (i.e.,
impulsive) responses; rather, they suggest that ADHD children
have an inefficient style of responding that results in slow and
inaccurate (i.e., inefficient) responses.
To address the second specific aim, we compared the 7-present
(n 5 13) and 7-absent (n 5 19) subgroups defined by the DRD4
7-repeat genotype. These two subgroups did not differ on the
severity of ADHD symptoms of inattention or hyperactivityy
impulsivity, which is not surprising, because the entry criteria for
the MTA study required that all subjects have severe symptoms
of ADHD. Also, the 7-present and 7-absent subgroups did not
differ in terms of average age, intellectual ability (as measured
by two subtests of an IQ test), academic achievement, medication
treatment, gender ratio, or ethnicity. The 7-present subgroup did
have somewhat higher ratings of ODD, but these subgroup
differences were not significant at P , 0.05.
The distributions of the RTs for the three tasks are presented
in Fig. 2, and the mean RTs and SDs for the subgroups are
presented in Table 2. Instead of showing the predicted abnor-
mality in performance on these neuropsychological tasks (i.e.,
longer RTs and greater SDs), the subjects in the 7-present
subgroup showed no significant abnormalities when compared
with the control group. The 7-absent subgroup, on the other
hand, showed, on average, longer RTs and greater SDs. Inspec-
tion of the distributions of RTs showed that, in the 7-absent
subgroup, depending on the task, 2–5 of the 19 subjects (about
17%) had RTs that did not overlap with the RTs of the control
group.
Because we predicted that the 7-present subgroup would show
the greatest abnormalities, any directional (one-tailed) test
would be nonsignificant. However, to clarify the observed group
differences, we performed post hoc or exploratory analyses using
two-tailed tests. To avoid the loss of power associated with
multiple tests and to gain reliability by the Spearman-Brown
method of combining tests, an ANOVA framework was used
with independent variables specified by Group (7-present, 7-ab-
sent, and control) and Task (color-word, cued-detection, and
go-change). An analysis was performed separately for the two
summary scores from each subject (RT and SD).
The Group 3 Task ANOVA of RT revealed significant main
effects of Group [F (2, 46) 5 3.68, P 5 0.033] and Task [F (2,
92) 5 134.88, P , 0.001], but the Task 3 Group interaction was
not significant [F (4, 92) 5 2.09, P . 0.089]. The Group marginal
means (average RT across tasks) were compared by two-sided
Dunnet’s t tests (41) for comparison of the two ADHD sub-
Fig. 1. Comparison of total ADHD group and the control group on the XNAT
battery
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groups to a common control. In our exploratory analysis, this
procedure was selected to maximize power by including the
largest group (the control group) in each comparison, instead of
making a comparison of the smaller ADHD subgroups. The
overall difference in RT was significant for the comparison of the
7-absent subgroup to the control group (mean difference 5 100
ms, standard error 5 40, P 5 0.033), but the comparison of the
7-present subgroup and the control group was not significant
(mean difference 5 20.8 ms, standard error 5 47, P 5 1.00).
(Because of the smaller sample sizes, the ADHD subgroups
differed significantly by one-tailed but not two-tailed tests).
The Group 3 Task ANOVA of average SD also revealed
significant main effects of Group [F (2, 46) 5 4.27, P 5 0.02] and
Task [F (2, 92) 5 59.50, P , 0.001]. The Group 3 Task
interaction was also significant [F (4, 92) 5 2.71, P 5 0.035]. The
Dunnet’s t tests for comparison to a common control revealed
that the 7-absent subgroup differed significantly from the con-
trol group for average SD (mean difference 5 78.8, standard
error 5 28.2, P 5 0.015), but that the 7-present subgroup did not
(mean difference 5 11.8, standard error 5 32.6, P 5 0.913).
Discussion
This study indicates that the 7-present genotype is not a neces-
sary condition for the manifestation of cognitive abnormalities
thought to be characteristic of children with DSM-IV diagnoses
of ADHD-combined type. Although the 7-absent subgroup
shows clear abnormalities in performance on these neuropsy-
chological tests of attention, the 7-present subgroup was free of
critical neuropsychological abnormalities thought to character-
ize children with psychiatric (DSM-IV) diagnoses of ADHD.
This suggests that the 7-repeat allele may identify a subgroup
with the behavioral but not the cognitive components of ADHD.
These findings led us to reconceptualize the possible association
of the DRD4 gene with ADHD and to align our clinical finding
with the literature on associations of the DRD4 gene with
Fig. 2. RT distributions for control, 7-present, and 7-absent groups.
Table 2. Mean RTs and SDs for the summary scores of the
neuropsychological tasks of the XNAT battery
ADHD 7-absent
ADHD
7-present Control
Mean SD Mean SD Mean SD
Color-word 1014.5 410.8 828.9 158.6 839.2 197.6
Cued-detection 435.9 86.1 412.4 54.9 394.1 49.1
Go-change 520.7 147.6 468.4 129.1 444.5 113.7
Average 657.0 214.8 569.9 114.2 559.3 120.1
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normal attention and behavior (for a critical review, see ref. 42).
According to this speculation, the 7-repeat allele of the DRD4
gene may be associated with extreme placement on a dimension
of personality (e.g., extraversion) or proposed dimensions of
temperament, such as novelty seeking (43, 44) or effortful
processing (see ref. 45). These children may be easily bored in the
absence of highly stimulating conditions (see ref. 46), may show
delay aversion and choose to avoid waiting (47), may have a style
difference that is adaptive in some situations (48), and may
benefit from high activity levels during childhood (e.g., ref. 49).
In contrast, for a complex disorder like ADHD, we suggest that
the 7-absent subgroup is most certainly nonhomogeneous, and
composed of individuals with other genetic abnormalities or non-
genetic etiologies. These could include (i) other alterations in the
highly variable DRD4 gene itself (see ref. 8) not analyzed in the
current study, (ii) alterations in other relevant genes such as DAT1,
(see ref. 2), and (iii) minimal brain damage (MBD) or dysfunction
(50–55). We propose that these other etiologies produce both the
behavioral abnormalities reflected as symptoms of ADHD and the
cognitive abnormalities reflected by longer RTs and SDs in the
neuropsychological tests of the XNAT battery. For example, the
observed cognitive abnormalities (i.e., slow and variable responses)
are very common sequelae of brain injury (56) that may in some
instances produce the symptoms of ADHD (57).
Of course, there are many limitations of this initial study. We
will list a few of these, which provide direction for our next steps
in the XNAT research program on ADHD. First and primary is
the small sample size for the ADHD subgroups. Despite a
relatively large number of subjects in the total ADHD group
(n 5 44), the numbers dwindled because of less than unanimous
consent for a blood sample (only 32y44 or about 75%). Even
though we have a consistent pattern of performance in our
sample, we realize it is likely that this pattern may be different
in another sample of ADHD children, and some informal
comparisons of 7-present and 7-absent subgroups in typical
ADHD samples have not duplicated our results (S. Smalley,
personal communication; X. Castellanos, personal communica-
tion). However, our sample size is comparable to the sample sizes
in the initial candidate gene studies of Alzheimer’s disease,
which contrasted groups on quantitative traits. In a study of
glucose metabolism as a quantitative trait that showed the
earliest decline in Alzheimer’s patients, Reiman et al. (58)
screened 235 subjects and accumulated only 11 e4 homozygotes.
This small group was compared with a group of 22 control
subjects. Plassman et al. (59) contrasted only 6 subjects with the
e4 genotype with 14 subjects without an e4 allele in a study of
hippocampal volume as a quantitative trait. As in these extraor-
dinarily important studies of Alzheimer’s disease, the analyses of
our small samples of ADHD subjects should be considered
exploratory. The primary use of the findings reported here
should be to generate hypotheses to be tested by planned
comparisons in future studies.
Second, the refined ADHD phenotype we used to select subjects
may limit the generalization of this study. The MTA entry criteria
(32, 33) selected subjects with ADHD-combined type, with onset of
symptoms by the age of 7 years, and with severity of symptoms
documented by parent and teacher ratings and confirmed by parent
interviews (structured and clinical). Thus, our results may not hold
for the other ADHD subtypes (inattentive type or hyperactivey
impulsive type) or to ADHD subjects with less pervasive or severe
expression of symptoms (see refs. 11 and 12).
Third, in this study, the comparison of the 7-present and
7-absent subgroups was not conditional on the parental geno-
types. Even though our data suggest that these DRD4 genotypes
may be useful in forming more homogeneous subgroups of
children with ADHD, it is possible that the 7-present and
7-absent subgroups differ on other factors than the status of the
DRD4 7-repeat allele. The quantitative trait extension of the
transmission disequilibrium test (TDT) (e.g., ref. 60) provides a
way to control for population stratification and other unknown
factors. For the comparison of group performance on RT and
SD measures derived from the XNAT battery of neuropsycho-
logical tests, a quantitative TDT would provide additional con-
trols. For example, Allison’s TDT-Q5 statistic uses genotype as
an independent variable, as we did in our analyses, but includes
only those subjects who are offspring of heterozygous parents
with a 7-repeat allele. Because almost all probands in the
7-present subgroup are informative (there are very few 7-repeat
homozygotes), the limiting factor is the number of probands in
the 7-absent subgroup who had parents with a 7-repeat allele that
was not transmitted. Therefore, a large sample, such as the total
MTA sample of 579 ADHD subjects, would be necessary to
accumulate a modest subsample of the informative cases for a
TDT evaluation of the hypothesis that these genotypes differ in
performance on tests of attention.
Fourth, a number of other genes have been implicated in
ADHD, including the dopamine transporter gene (2) and other
dopamine receptor genes (42). The independent or interactive
effects (see ref. 60) of multiple genes deserve investigation.
It is clear that additional studies will be needed to understand the
molecular bases of ADHD. Some investigators are using genome
scans and linkage methods in the hope of identifying other genomic
regions associated with ADHD. We are focusing on direct DNA
sequence analysis of the DRD4 gene region, in an attempt to
determine whether specific variants of this highly polymorphic gene
(5–10) play important roles in the etiology of ADHD.
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